RE:RE:Theralase Is still Flying Under the Radar
I'm not sure but if Dr. Kamat is on the advisory boards for a company he may be extra cautious about raising it while the data is still incomplete. I don't know which other companies he advises but I could see it looking suspicous if he says that he is excited about a tiny canadian company's drug, before it is really ready for the full press. Sometimes you have to overcompensate to look impartial.
But that is just my speculation.